content-documents/house-oversight-nov/16/HOUSE_OVERSIGHT_024100.md

---
title: "House Oversight: Estate Documents (Nov 12) (HOUSE_OVERSIGHT_024100)"
source: "House Oversight: Estate Documents (Nov 12)"
sourceUrl: "https://www.justice.gov/epstein"
date: "2026-01-01"
category: "House Oversight"
eftaNumber: "HOUSE_OVERSIGHT_024100"
ocrPages: 1
ocrChars: 3118
ocrElapsed: 0.0
parseTier: "external-legacy"
engine: "engine undisclosed (ep-nov-12.greg.technology mirror)"
externalSource: "greg-ep-nov-12"
externalLicense: "not granted"
externalCredit: "ep-nov-12.greg.technology"
externalUrl: "https://ep-nov-12.greg.technology"
---

XIII. APPENDICES
Appendix 1
Listing of Investments by Fund
New Leaf Ventures II, L.P.
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes ,],K,L,M and N in this Appendix.
Company
Sector
Realized or Partially Realized Investments
Acadia Phamaceuticals, Inc.
Ambit Biosciences, Inc.
Array Biopharma Inc.
Audax Health Solutions, Inc.
Chimerix, Inc.
Epizyme, Inc.
Glumetrics, Inc.
Intercept Pharmaceuticals, Inc.
Kalidex Pharmaceuticals, Inc.
MEI Pharma, Inc.
Presidio Pharmaceuticals, Inc.
Synageva BioPharma
Worldheart, Inc.
Therapeutics
Therapeutics
Therapeutics
Convergence
Therapeutics
Therapeutics
Diagnostics & Infrastructure
Therapeutics
Therapeutics
Therapeutics
Therapeutics
Therapeutics
Healthcare Devices
Total Realized or Partially Realized Investments
Advanced Cell Diagnostics, Inc.
Afferent Pharmaceuticals, Inc.
Altura Medical, Inc.
AwarePoint Corporation
Calchan Holdings LTD
CardioKinetix, Inc.
Convergence Pharmaceuticals, Ltd
Durata Therapeutics, Inc.
iRhythm Technologies, Inc.
Karos Pharmaceuticals, Inc.
Karus Therapeutics Ltd
Karyopharm Therapeutics, Inc.
Kitcheck, Inc.
Neuronetics, Inc.
NY Digital Health, LLC
Oxford Immunotec
Principia BioPharma, Inc.
Spiracur, Inc
TigerText, Inc.
Treato Pharma
Truveris, Inc.
Versartis, Inc.
Public Investments
Diagnostics & Infrastructure
Therapeutics
Healthcare Devices
Convergence
Therapeutics
Healthcare Devices
Therapeutics
Thera peutics
Convergence
Therapeutics
Therapeutics
Therapeutics
Convergence
Healthcare Devices
Convergence
Diagnostics & Infrastructure
Therapeutics
Healthcare Devices
Convergence
Convergence
Convergence
Therapeutics
Therapeutics
Total Unrealized Investments
Total New Leaf Ventures II, L.P. Investments
Vintage
Year
2012
2013
2012
2011
2011
2013
2008
2012
2011
2012
2009
2009
2008
2012
2009
2010
2011
2011
2011
2010
2009
2011
2010
2012
2013
2013
2009
2012
2009
2011
2009
2012
2013
2012
2011
2011
Total Cost
$
$
$
$
$
$
7.7
10.4
9.0
3.8
20.6
3.4
10.7
10.5
2.4
9.0
11.0
10.4
17.0
125.9
9.0
11.2
10.7
12.8
5.2
12.0
7.4
25.0
11.1
7.6
5.8
1.0
3.7
20.3
0.4
11.3
9.7
12.0
4.6
3.0
6.5
21.2
20.6
232.1
358.0
89
Realized
Unrealized
Value
Value
$
$
$
19.4
11.1
20.3
12.5
27.0
6.8
34.1
0.2
10.2
75.7
1.8
219.2
0.1
0.0
13.1
13.2
$
$
-
$
$
1.6
44.9
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
232.4 $
35.8
82.3
9.0
11.2
8.3
14.1
12.0
7.6
40.8
11.6
7.5
5.8
4.2
3.7
21.9
0.4
27.1
9.7
8.5
5.6
3.0
6.5
93.6
29.5
341.4
423.7
Total
Value
Gross
Multiple
Realized
Portion)
Gross
Multiple
(Total)
Gross IRR
$
$
$
$
$
$
$
$
$
$
19.4
11.1
20.3
14.1
71.9
6.8
34.1
0.2
46.0
75.7
1.8
301.5
9.0
11.2
8.3
14.1
N
354.6
656.1
2.51
1.06
2.25
3.07
2.03
3.24
0.07
2.94
7.30
0.11
2.01
2.01
2.51
1.06
2.25
3.68
3.50
2.03
3.24
0.07
5.12
7.30
0.11
2.39
1.00
1.00
0.77
1.10
1.00
1.03
1.63
1.04
1.00
1.00
4.17
1.00
1.08
1.00
2.41
1.00
0.70
1.25
1.00
1.00
4.41
2.07
1.53
1.83
581.9%
13.1%
74.0%
105.6%
57.7%
1583.0%
NM
323.6%
-91.6%
423.2%
NM
103.3%
NM
40.6%
-0.4%
0.0%
-12.3%
5.7%
NM
0.0%
1.0%
21.2%
1.6%
0.0%
0.0%
1638.7%
0.0%
2.0%
0.1%
28.3%
0.0%
-8.4%
22.6%
0.0%
0.0%
129.4%
42.5%
20.4%
29.6%
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024100